Herve Hoppenot has traded his title of president of Novartis’s oncology division for president and CEO of Incyte.
Novartis posted the departure notice Sunday, and Incyte published its corporate hiring notice Monday.
Hoppenot’s job changed literally overnight. Novartis said Alessandro Riva will step into Hoppenot’s now-former role until the company finds a replacement, in addition to keeping abreast of his responsibilities as the global head of Novartis oncology development and media affairs.
Hoppenot’s move closes out 10 years with the Basel, Switzerland, drugmaker. PMLive notes that this tenure included launching Jakavi for myelofibrosis in 2011 and Signifor for Cushing’s disease in 2012, as well as finding new indications for established drugs, including cancer meds Afinitor and Tasigna.
